Nova Pharma, the official distributor of VetPlus products in the Gulf Region, hosted a VetPlus seminar at the Movenpick Jumeirah Beach Hotel on the 6th and 7th November 2012.
The event was attended & welcomed by over 100 delegates from veterinary practices in UAE, Bahrain, Oman & Qatar.
VetPlus started its operations in the UK in 1995 having two single visions –make the best quality nutraceutical product for the pets and sell them only though veterinarians. Almost 20 years later, they are now recognised as a global leader in veterinary nutraceuticals.
They were the first company to develop and patent a joint supplement for dogs, SYNOQUIN®, which is today the number one joint supplement recommended by UK veterinarians.
Over the last ten years several more products have been introduced, five of which are today market leaders within their sectors. With a growing demand for its products both domestically and abroad, VetPlus is committed to continue its history of innovation.
Mr. Neil Pullar, International Sales Director, VetPlus highlighted the growing trend of the veterinary nutraceutical market and explained how VetPlus endeavor to obtain veterinary confidence through their clinical trial work, “We are one of the very few nutraceutical companies in the world to invest in clinical trial work and we do this in order to instill confidence in the veterinarians of the efficacy and quality of our products. Furthermore, the fact that our products are and always will be sold through veterinary clinics, relays our commitment to the independent veterinary clinic practices”
The statistics & figures quoted by Mr. Pullar stunned the delegates as he relayed that the market forecast for veterinary Nutraceuticals is expected to grow by 50% in 2015, reaching figures of $2 Billion.
An overview of the VetPlus product range was presented by Ms. Sharon Maguire, Veterinary Territory Manager, Nova Pharma. She explained that the companion animal range includes more than 20 products which can be used in the management of brain & behavior conditions, joint mobility issues, skin & coat conditions, gastro-intestinal and internal clinical conditions including, EPI, FIC & UTIs. She also referred to one of the new launches of Vet Plus, COMPLIVIT®, a high calorie nutritional supplement containing essential vitamins, amino acids & prebiotics for use in cats & dogs.
Dr. Ann Burns MVB MRCVS, International Technical Advisor VetPlus, delivered the second part of both evenings. The focus for the first evening discussed The Clinical Role of Nutraceuticals in Internal Medicine with a Focus on Gastrointestinal Disease. The disease process, management options and the value of the VetPlus gastro-intestinal products SAMYLIN®, PROMAX® & LYPEX® were reviewed and discussed. She also touched on the” ground breaking research” of the most recent VetPlus clinical trial where LYPEX® Capsules, with its unique enteric coated capsule design for the treatment of exocrine pancreatic insufficiency was reviewed. The results showed clearly that LYPEX® with its enteric coating makes the pancreatic enzymes more effective and resulted in greater clinical results than in the noncoated equivalent.
Dr. Ann stated that the trial “represents a considerable advance on the prior state of knowledge regarding EPI therapy and has won the award for the best gastroenterology abstract at the ECVIM 2012 congress”
The second evening’s clinical focus topic was the recognition and management of common behavioural problems in cats and dogs and the presentation served as a suitable method of introducing CALMEX CAT® & CALMEX DOG®, which have now been officially launched through Nova Pharma in veterinary clinics.
Speaking afterwards, Dr. Ben Youssef, Managing Director of Nova Pharma, complemented the VetPlus international team in helping to “raise awareness of the value of these Nutraceuticals in practical settings in clinical practice”.
To find out more information on VetPlus products and find out how this range can benefit your practice, please contact info[@]novapharma.com